Antimicrobial Resistance Becomes a Health-System Design Problem

Antimicrobial resistance is usually described as a prescribing problem. Clinicians prescribe too freely, the argument goes, and stewardship programmes exist to restrain them. That framing has produced useful discipline, but it is no longer sufficient. Resistance is shaped by diagnostic capacity, local surveillance, infection prevention, procurement decisions and the fragile economics of antibiotic development. Health systems that treat stewardship as a compliance box rather than an operating model are the ones most exposed.

The distinction matters for the 2026 Global Healthcare Awards. Stewardship is moving from a narrow clinical specialism into a governance and operational-excellence theme that touches laboratories, wards, boardrooms and supply chains. The question is no longer only whether a hospital has an antimicrobial stewardship committee. It is whether the institution has built the infrastructure that makes wise prescribing possible.

Why Prescription Restrictions Reach Their Limits

Restriction and preauthorisation remain useful tools. They can curb unnecessary use of broad-spectrum agents, prompt specialist review and reduce variation in prescribing. But they operate at the point of decision, often after diagnostic uncertainty has already shaped the choice. A clinician facing a sick patient cannot always wait days for a culture result. Empirical prescribing becomes the practical default, and stewardship review arrives after the fact rather than guiding the decision.

That is why diagnostics are the real bottleneck. Without rapid, accessible testing that can distinguish bacterial from viral infection, identify likely pathogens or flag resistance markers, stewardship guidance remains abstract. Clinicians are asked to use antibiotics judiciously without the information needed to judge. A stewardship programme built mainly on restrictions can then become guesswork with an audit trail.

Diagnostic capacity is not only a matter of sophisticated equipment. It depends on laboratory staffing, sample transport, turnaround times and the ability to communicate results into clinical workflows. Where those elements are weak, even good stewardship policy struggles to change behaviour. The infrastructure gap is also an equity gap: many health systems lack the testing that stewardship guidance assumes.

Local Data and Surveillance as Operating Infrastructure

Resistance patterns are local. A hospital’s intensive care unit, surgical wards and outpatient clinics may face different pressures, and national averages can obscure the risks that matter at the bedside. Effective stewardship therefore depends on surveillance systems that connect microbiology results, dispensing records and clinical outcomes rather than relying on periodic reports or external benchmarks.

Linked data allows a hospital to see where resistance is rising, which organisms are circulating, how antibiotics are actually used and whether treatment decisions are associated with good or poor outcomes. It supports local antibiograms, syndrome-specific guidance and targeted audit. It can also inform procurement forecasts, helping pharmacy teams anticipate demand for reserve agents and avoid the substitutions that follow shortages.

The technical requirements are substantial but familiar: interoperability between laboratory and pharmacy systems, clear data governance, analytical capacity and clinical ownership of the results. The organisational requirement is harder. Data must become part of routine management rather than a project owned by a single department. Stewardship works better when surveillance is an operating system, not an annual exercise.

Infection Prevention Is the Low-Tech Core

Prescribing restrictions cannot compensate for weak infection prevention. Hand hygiene, device management, environmental cleaning, isolation capacity and adequate staffing often matter more than formulary rules. These are unglamorous practices, but they determine whether resistant organisms spread through wards and whether patients need antibiotics in the first place.

Infection prevention is also a design issue. Crowded wards, insufficient isolation rooms, poor ventilation and workflow pressures can undermine even well-trained staff. Outbreak response depends on the ability to separate patients, trace contacts and communicate quickly across departments. Those capabilities require capital, planning and management attention, not just clinical reminders.

Health systems that treat infection prevention as a low-cost compliance activity tend to pay later. The returns from basic practice are difficult to measure in a single budget cycle, but they are central to any credible resistance strategy.

The Pipeline and Procurement Problem

New antibiotics remain commercially difficult to develop. A product that is used sparingly, reserved for resistant infections and subject to stewardship controls may generate limited revenue, while development costs remain high. That mismatch has prompted debate about pull incentives, subscription-style payment models and procurement commitments that reward availability rather than volume alone.

For hospitals, the practical question is access. A stewardship programme that recommends reserve antibiotics is of little use if those medicines are unavailable, unaffordable or subject to recurring shortages. Procurement decisions therefore have clinical consequences. Contracts that consider supply security, not only lowest price, can reduce the risk of forced substitutions and treatment delays.

Stewardship and procurement should not sit in separate silos. Both shape which medicines are used, how reliably they are supplied and whether clinicians can follow guidance when resistance is confirmed. The pipeline problem is usually discussed at the level of national policy, but its effects are felt in hospital pharmacies and on wards.

Governance, Equity and Accountability

Stewardship needs board-level reporting and clear ownership across clinical and pharmacy leadership. Metrics should reflect patient outcomes, safety and resistance patterns rather than prescription volume alone. A programme that reduces antibiotic use while missing infections or delaying treatment has not succeeded. Governance should make those trade-offs visible.

There is also an equity dimension. Access and excess coexist. Some health systems overuse antibiotics while others lack the diagnostics and effective medicines that stewardship guidance assumes. A global approach has to recognise that the same policy prescription does not fit every setting. Infrastructure, not just instruction, determines what is possible.

That is why antimicrobial resistance is best understood as a health-system design problem. It requires rapid diagnostics, linked surveillance, credible infection prevention, reliable procurement and accountable governance. The Global Healthcare Awards recognise practical excellence in healthcare delivery, and stewardship belongs in that conversation: not as a slogan about prescribing, but as a test of how well health systems organise information, supplies and responsibility around a shared clinical risk.